This section provides a brief overview of our most popular immuno-oncology biomarkers. We have developed a non-invasive method to look at activation of T-cells, macrophages and neutrophils. Understand pharmacodynamics, Mode of Action and efficacy non-invasively. 

Therefore, it is important to identify patients with a T-cell permissive tumor microenvironment.

More about our biomarkers for Immuno-Oncology

Find publications

Patients with a severe desmoplastic reaction have a significantly reduced response to checkpoint inhibitor treatment due to fibrotic involvement of the tissue. We can pinpoint patients with a low desmoplastic reaction, and thereby patients that are likely to survive due to correct treatment. Read below about how you can utilize that in your clinical program. 

More about our biomarkers for desmoplasia (tumor fibrosis)

Find publications

At Nordic Bioscience we are experts in looking at different tissues in a protein-level. That approach has been applied to the oncology field as cancer biomarkers, in order to evaluate how treatment improve the tissue in specific regions. We set us apart from other circulating biomarkers (such as ctDNA or CSCs) by a patient centric approach and utilizing our knowledge in precision medicine to understand the cancer biology in the individual patients. Read more about our biomarkers for cancer indications here, and how we can profile the cancerous stroma.

More about our biomarkers for the tumor stroma

Find publications

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.

We use cookies on our site to enable essential services and functionalities, and collect data in regards to visitor information. This is done in order to provide the best possible experience for the visitor. Cookie policy Privacy statement